Partners in Practice Articles

Renuka Iyer, MD, Co-Director, Liver and Panc

by Steven Nurkin, MD, MS

Our Gastrointestinal Surgery program offers many modalities to provide individualized, tailored treatment for our patients with colorectal cancer.

Alex Adjei, MD, PhD, Senior Vice President of Clinical Research and Katherine Anne Gioia Chair in Cancer Medicine, describes how the Department of Medicine at Roswell Park serves as a "stand-alone cancer center" within the larger comprehensive cancer center of Roswell Park.

Mitogen-activated protein kinase (MAPK) is a key signaling pathway in a number of cancers.

Neuroendocrine and carcinoid tumors are rare and it takes specialized skills and equipment to diagnose them. Because symptoms may not appear, tumors are often discovered when tests and procedures are performed for other purposes.

High constitutive activity of MAPK pathway has been shown in a majority of melanomas. To date, BRAF and MEK have been shown to be clinically relevant components of this pathway with proven efficacy of agents targeted to BRAF and MEK.

BRAF mutations have been reported in 3% of non-small cell lung cancers (NSCLC), only in adenocarcinoma sub-type of NSCLC. Although uncommon, BRAF mutations represent a valid potential target as multiple RAF kinase inhibitors are available. BRAF V600E mutation is reported in 2% of NSCLC.

BRAF mutation has been reported in approximately 10–15% of colorectal cancers. Data also supports presence of BRAF mutations as a poor prognostic factor, as well as a potential biomarker of lack of response to EGFR directed therapy in KRAS wild type colorectal cancer.

Michael is available to address your questions, concerns and feedback. To enhance the connection between your practice and Roswell Park, contact Michael at any time.